摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-diethylaminoethyl)piperidine-4-carboxaldehyde | 1062587-10-3

中文名称
——
中文别名
——
英文名称
1-(2-diethylaminoethyl)piperidine-4-carboxaldehyde
英文别名
1-[2-(Diethylamino)ethyl]piperidine-4-carbaldehyde
1-(2-diethylaminoethyl)piperidine-4-carboxaldehyde化学式
CAS
1062587-10-3
化学式
C12H24N2O
mdl
——
分子量
212.335
InChiKey
RTBFHRCQHFUIOQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    15
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-(2-diethylaminoethyl)piperidine-4-carboxaldehyde2,3-二氨基苯甲酸乙酯 在 copper diacetate 作用下, 以 甲醇 为溶剂, 反应 0.5h, 生成
    参考文献:
    名称:
    Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer
    摘要:
    We have developed a series of cyclic amine-containing benzimidazole carboxamide poly( ADPribose) polymerase ( PARP) inhibitors, with good PARP-1 enzyme potency, as well as cellular potency. These efforts led to the identification of a lead preclinical candidate, 10b, 2-(1-propylpiperidin-4-yl)-1H-benzimidazole- 4-carboxamide (A-620223). 10b displayed very good potency against both the PARP-1 enzyme with a K-i of 8 nM and in a whole cell assay with an EC50 of 3 nM. 10b is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide ( TMZ) and in an MX-1 breast xenograph model in combination with cisplatin. (c) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2008.05.044
点击查看最新优质反应信息

文献信息

  • Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer
    作者:Thomas D. Penning、Gui-Dong Zhu、Viraj B. Gandhi、Jianchun Gong、Sheela Thomas、Wilfried Lubisch、Roland Grandel、Wolfgang Wernet、Chang H. Park、Elizabeth H. Fry、Xuesong Liu、Yan Shi、Vered Klinghofer、Eric F. Johnson、Cherrie K. Donawho、David J. Frost、Velitchka Bontcheva-Diaz、Jennifer J. Bouska、Amanda M. Olson、Kennan C. Marsh、Yan Luo、Saul H. Rosenberg、Vincent L. Giranda
    DOI:10.1016/j.bmc.2008.05.044
    日期:2008.7
    We have developed a series of cyclic amine-containing benzimidazole carboxamide poly( ADPribose) polymerase ( PARP) inhibitors, with good PARP-1 enzyme potency, as well as cellular potency. These efforts led to the identification of a lead preclinical candidate, 10b, 2-(1-propylpiperidin-4-yl)-1H-benzimidazole- 4-carboxamide (A-620223). 10b displayed very good potency against both the PARP-1 enzyme with a K-i of 8 nM and in a whole cell assay with an EC50 of 3 nM. 10b is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide ( TMZ) and in an MX-1 breast xenograph model in combination with cisplatin. (c) 2008 Elsevier Ltd. All rights reserved.
查看更多